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Non-Selective Primary Human Tumor Cell Line Generation from Surgical 
Resections to be Paired with Flash Frozen and Paraffin Embedded Tissue: 





Translational cancer research relies on the availability of human patient tissue demonstrating the 
specific disease process under investigation. Biobanks of human tissue have historically been 
and remain to date the primary access point for cancer research samples. Biorepositories 
routinely supply researchers with varying sample types for use in biomedical studies, most 
commonly formalin-fixed and paraffin-embedded (FFPE) tissue or fresh snap-frozen tissue. In 
conjunction with preserved tissue samples, viable tumor cell lines derived from patient tissue 
have emerged to be a new gold standard in cancer research, particularly in drug discovery and 
functional prognostic assays. Tissue banks providing these samples are being termed “next-
generation” and are adapting to directly assist researchers by performing high throughout 
technical studies, such as routine histology and immunostaining of donor tissue. These high-
quality, next-generation biorepositories are a relatively scarce resource in the broader research 
community in the United States and have traditionally been associated with large centralized and 
very well-established university medical centers. This article describes the next-generation 
resources now available at the Edwards Comprehensive Cancer Center with its association with 
the Marshall University Joan C. Edwards School of Medicine in Huntington, West Virginia. This 
manuscript details the procedures, protocols, and success rates of the Tissue Procurement 
Program (TPP) to generate a growing cohort of viable primary human tumor cell lines 
representing varying malignancies to be used in conjunction with matched formalin-fixed and 
paraffin-embedded (FFPE) and snap-frozen tissue samples for comprehensive translational 
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Introduction 
 
To facilitate translational cancer research and to further improve the treatment of the disease, 
biorepositories have emerged to provide for the need for representative samples for study and 
testing. From these libraries of preserved human tissue, scientists have made significant 
advancements in understanding and subsequently treating these diseases in the last few decades.1 
However, as the body of knowledge has continued to grow on the subject, it has revealed even 
more questions about cancer biology that have yet to be answered. Now the field is shifting to 
not only more in-depth studies of tumor composition, molecular makeup, and druggable targets, 
but also into tumor behavior and its interaction with surrounding normal tissues and other body 
systems. 2,3 Traditional, first-generation biobanks have focused primarily on the acquisition and 
storage of formalin-fixed and paraffin-embedded (FFPE) or fresh frozen tissue. This source of 
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patient material is an integral part of routine pathologic studies in the clinical setting and has 
played a significant role in cancer research to date.4 However, in the emerging era of 
personalized medicine, non-viable tissue samples have limited research potential when compared 
to viable patient-derived cell cultures. Viable primary tumor cell cultures allow for the discovery 
and validation of therapeutic targets and treatment modalities in addition to prognostic studies 
and tumor biomarker discovery via functional assays on living cell populations.5 Recently, the 
tissue procurement biorepository at the Edwards Comprehensive Cancer Center developed a 
non-selective protocol for the generation of viable primary tumor cell cultures to better meet the 
current needs of translational research. The protocol has been successful in generating primary 
cell cultures representing varying tissue types suitable for in-vitro studies, which can be paired 
with snap-frozen tissue samples and formalin-fixed and paraffin-embedded (FFPE) samples to 
provide comprehensive data for rapid advancement in the field. The protocols outlined for 
primary cell line generation and storage have been standardized across varying solid tumor types 
and have been tailored to allow for rapid, minimally selective in-vitro tumor expansion. The 
expanded diverse tumor populations are then assessed for quality and integrity by direct 
immunohistochemical comparison to the corresponding tissue of origin by a board-certified 
pathologist.   
 
Second Generation Biobanks Provide Superior Resources for Translational Research 
by Combining Clinical Grade Source Material in Conjunction with Proteomic-Compatible 
FFS Tissue and Functional Live Cell Culture Samples  
 
In the clinical setting, a large number of tissue samples are obtained in hospital pathology 
laboratories daily for diagnostic purposes. These samples vary widely; however, a significant 
portion of these samples represent surgical tumor resections. These resection specimens are 
dissected by certified pathologists and pathology assistants in a process called gross pathology 
examination. Representative sections of the tumor resection specimens are then taken for 
diagnostic workup and preserved in formalin-fixed and paraffin-embedded (FFPE) tissue blocks. 
4,6,7 Representative slides are then cut from these tissue blocks for routine histologic staining and 
diagnosis. This process is essential to clinical diagnostics and is used to evaluate a patient’s 
condition and to determine further treatment plans.8 After the diagnostic workup is complete, 
these preserved tissue samples may be stored for many years. In most cases, however, not all of 
the resected tissue is needed for diagnosis. The excess tissue may be acquired with the consent of 
the donor by a research biobank for further translational research studies. These samples have 
been the primary research source material for decades and have been used to further biomedical 
cancer research. 4,5,6,7,8 FFPE samples, however, are not without their limitations, as they may not 
retain intact genomic and proteomic data.9 With the emergence of molecular pathology, in 
conjunction with traditional histological staining techniques, snap-frozen tissue has also become 
a valuable resource for furthering cancer research. At the time of gross dissection, fresh tissue 
samples may be flash-frozen in liquid nitrogen to retain their molecular composition. This 
enables researchers to extract proteomic data from the samples to map out enzymatic pathways 
associated with the drivers of cancer and to identify therapeutic targets for drug development.10,11 
In the clinical setting, flash-frozen samples have not yet become a routine modality used for 
diagnostics; however, in translational research, these samples have proven to be invaluable. In 
addition to the collection of fresh frozen tissue samples (FFS), certain tumor resection specimens 
are selected for the generation of primary tumor cell cultures (TCC). These cultures represent 
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non-selective total living populations of clonal tumor cells and associated neoplastic cell 
populations to be used in functional translational studies. 5,12,13,14 Combining the primary human 
tumor cell cultures (TCC), the collected fresh-flash frozen samples (FFS), and the FFPE tissue 
blocks allows for researchers to have a complete comprehensive representative model of the 
disease of study. In drug development studies, for example, researchers can identify, quantify, 
and then assess the in-vitro activity of therapeutic targets for future anti-cancer drug 
development. Herein, we describe the routine longitudinal collection of FFPE tissue samples 
along with matched FFS samples and the generation of matched histopathological consistent 
primary tumor cell lines to be placed into our biorepository at the Edwards Comprehensive 
Cancer Center for increased access to research materials for biomedical research at rural 
institutions.  
 
Acquisition of Human Tissue for Biobanking: From the Body to the Benchtop  
  
Possible patient donors are screened by the tissue procurement staff before consenting based 
upon multiple criteria. These criteria primarily include the patient’s history of cancer, size of the 
tumor, and scheduled surgical procedures. Once the patient has been screened and meets 
acceptable criteria, they are presented with an informed consent (IRB # 112274) that details the 
release of excess tissue to the tissue bank to be distributed to requesting researchers. Once a 
patient has consented, the tissue bank staff notifies the clinical pathology laboratory. 
Coordination between the surgeon, operating staff, and pathology laboratory ensures that the 
surgical resection specimen arrives at the laboratory within minutes of surgery without any 
added fixatives or preservatives. The surgical specimen is then examined by certified pathology 
assistants under the supervision of board-certified pathologists to identify neoplastic tissue and to 
determine if the culture deems further processing. The remaining specimen will then be further 
processed by the pathology department for routine diagnostics and will result in the FFPE tissue 
blocks. The collected specimens will be held pending the final pathology diagnosis before 
formally being accepted into the biobank. Once the diagnosis is confirmed, the collected samples 
are cataloged on the tissue bank website powered by Openspecimen ® to be viewed and 
requested by researchers. The process from consent to specimen dispensation is outlined in 
Figure 1. Matched samples of grossly neoplastic tissue and corresponding non-neoplastic tissue 
from the surgical specimen are harvested and flash-frozen in liquid nitrogen at -196℃ for 
storage. The samples are de-identified and assigned a progressive recording specimen number. 
At this point, an additional representative sampling of the grossly neoplastic tissue is collected 
and placed into a tissue culture medium comprised of a basal solution of RPMI-1640 
supplemented with 10% FBS (fetal bovine serum) and 2% PS (penicillin/streptomycin). The FFS 
tissue samples are then transferred to liquid nitrogen storage drawers and cataloged while the 
tissue for cell culture generation (TCC) is provided to the laboratory tissue.  
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Clinical Grade Formalin-Fixed and Paraffin-Embedded Tissue Samples 
 
Currently, formalin-fixed and paraffin-embedded tissue samples remain the gold standard in 
pathologic diagnosis in the clinical setting.4,6,7 Routine diagnostics are run on these samples to 
detect the presence of disease on a histologic and cellular level. The utilization of FFPE tissue 
samples via immunohistochemical analysis with light microscopy continues to increase in scope 
with the inclusion of antibody and proteomic targeted special stains to subclassify various 
disease processes.15,16,17 Once properly processed and embedded, numerous representative tissue 
slides can be cut from the FFPE tissue samples to perform a plethora of varying diagnostic tests. 
In addition to standard of care diagnostics, these tissue samples can be used as a valuable source 
of primary research material for translational cancer research. FFPE has been one of the primary 
source materials for identifying and quantifying druggable targets for cancer, including the PDL-
1(programmed death ligand-1), HER1/2 (human epidermal growth factor receptor), and ER 
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(estrogen receptor) pathways, to name a few.15,17,18 The Tissue Procurement Program at the 
Edwards Comprehensive Cancer Center allows for researchers to request representative slides of 
various malignancies to further their research in hopes to continue to elucidate the mechanisms 
of carcinogenesis and to identify even more druggable targets to improve both cancer diagnostics 
and treatments. Also, with the partnership that the program has established with the pathology 
department of the Marshall University Joan C. Edwards School of Medicine, the entirety of the 
FFPE tissue samples from consented patients may be released to researchers following the 10-
year clinical archival period mandated by federal regulations.  
 
Flash-Frozen Tissue Samples: Translational Research Potential  
The importance of flash-frozen tissue samples lies in the utility they have in representing the 
core genetic composition of tumor specimens. Genetic information, including DNA, RNA, and 
proteins, is well preserved in FFS. Structures from FFS can be isolated in non-denatured active 
forms. Research has found that the DNA extraction rate, using either laboratory methods or 
commercial kits in fresh-frozen samples of the human brain, is 100%.10 Furthermore, the length 
of time the tissue had been stored did not affect the extraction rate.10 In contrast, FFPE samples 
were found to have a lower DNA extraction rate using the same methods. The length of storage 
time and PCR measures also appeared to affect whether DNA extraction from FFPE samples was 
successful.10  Several studies have also shown that FFS is optimal for RNA isolation.11,18  When 
RNA from FFS and FFPE were compared, the relative level of gene expression for each gene 
appeared to be conserved between sample types. However, gene expression patterns did not 
correlate between the two types of samples due to significant RNA degradation seen exclusively 
in FFPE materials.19 While normalization measures can compensate for RNA fragmentation in 
FFPE, these extra steps are not required at all for RNA from FFS. Furthermore, FFPE RNA that 
has undergone normalization measures can yield expression profiles consistent with FFS 
specimens, but FFS is still required to be used as a reference for the FFPE material.11 In addition 
to DNA and RNA extraction, proteins have high efficacy of being extracted from FFS with 
minimal molecular breakdown. Proteomic methods including laser capture microdissection and 
mass spectrometry can be used to identify well-preserved proteins from FFS. This information 
can then be implemented to designate biomarkers and ensure samples maintain tumor 
heterogeneity among other uses.20 
Primary Non-Selective Human Tumor Cell Line Generation 
The representative fresh tissue samples from grossly identifiable neoplastic tissue were cut from 
selective surgical resection specimens and collected in RPMI-1640 (Thermo Fisher Scientific) 
tissue culture medium supplemented with 10% Fetal Bovine Serum (Thermo Fisher Scientific) 
and 2% penicillin/streptomycin solution. These selected tissue samples were immediately 
transferred to the tissue culture laboratory where mechanical dissociation with a sterile scalpel 
and enzymatic dissociation with .25% Trypsin ® (Thermo Fisher Scientific) were performed to 
homogenize the tissue and begin the process of isolating out neoplastic cell populations. The 
tissue homogenates were then placed in tissue culture incubators (Heracell Thermo Fisher 
Scientific) to be cultured in an environment of 37℃ in a high humidity water jacket incubator in 
the presence of 5% atmospheric CO2. The tissue sample homogenates were then subsequently 
monitored, and the culture medium was changed at average three-day intervals. Adherent tumor 
cells were isolated from the associated non-neoplastic connective tissue with subsequent media 
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changes, and clonal non-selective cell populations were subcultured and passaged with the use of 
enzymatic dissociation using 0.25% Trypsin ® cell detachment solution (Thermo Fisher 
Scientific). The monolayer cultures were grown and assessed throughout the process for cell 
number and viability using Trypan blue exclusion and Cellometer-Mini Automatic Cell Counter 
System (Nexcelom). The target population size of 1x106 cells was determined to be the cutoff for 
sufficient cell growth and inclusion into the established primary cell culture biobank. Average 
culture periods ranged greatly among the samples reported in this study (Figure 2), and time to 
establish viable cell cultures was influenced by various factors, including initial sample size, 
purity and viability of the initial sample, growth rate of the tumor, type of malignancy, and level 
of adherence to the monolayer culture vessel. The success of the establishment of the selected 
tumor tissues varied greatly by tissue type in addition to the presence of contaminating agents, 
including bacteria and yeast. (Figure 3). The cell populations were then collected and transferred 
to a freezing medium composed of 90% Fetal Bovine Serum (FBS) and 10% Dimethyl-sulfoxide 
(DMSO) for frozen storage at vapor-phase liquid nitrogen. Representative cultures of the 
primary cell lines were grown directly onto glass slides for quality assessment and culture purity 
and sample integrity. These slides were then processed and stained by rapid hematoxylin and 
eosin (H&E) staining for direct comparison to the tissue of origin by a board-certified 
pathologist. Prepared slides of the primary tumor cultures were directly compared to diagnostic 
slides of matched tumor samples by the pathologist for quality assurance. The cultured 
monolayers were assessed for phenotypic similarity to the tissue of origin and confirmation of 
clonal tumor cell proliferation. Metrics including retention of secondary phenotypic 
characteristics (i.e., intracellular mucin, mitotic figures, cytoplasmic space, nuclear 
pleomorphism, intercellular-bridging, and inclusion bodies) were scored to determine the overall 
consistency of the derived cell lines to their corresponding tissues of origin. These secondary 
phenotypic characteristics are specific to neoplastic cells of varying etiologies and lineages. 
Mitotic figures and nuclear pleomorphisms are important cytological indicators of cancer grade 
and dedifferentiation. Intracellular mucin, inclusion bodies, and intracellular bridging serve as 
indicators of a specific tissue of origin and may also serve in the further subclassification of a 
variety of neoplasms. This information was cataloged for each selected sample and was 
incorporated into the Openspecimen ® biobank database for reference by requesting researchers. 
These living models of disease can provide researchers with valuable materials to run functional 
assays on specific disease models to develop new therapies and improved diagnostics. 
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Comprehensive Tri-Fold Resources Cataloged and Displayed in Interactive Online 
Database Openspecimen ® 
 
The complete specimens consisting of FFS, FFPEs, and living cell cultures are cataloged into the 
Openspecimen ® online database for open source access by researchers. Utilizing the 
Openspecimen ® biorepository software, researchers can easily query the tissue bank archives 
for the desired sample types representing their specific disease of study. The software interface 
displays the quantity and source type of each sample and allows rapid screening of samples in 
our archives for specific criteria (Figure 4). From the interface, researchers can request and view 
specific sample information, including brief de-identified patient history and complete 
pathologic diagnosis. Researchers can then submit sample requests to our biorepository staff and 
may also request additional clinical research services, including specialized 
immunohistochemical studies, pathology consultation, send-out molecular studies, and 
specialized sample preparation. Applications can also be filed by researchers to partner with the 
tissue bank for specialized sample collection for IRB-approved research protocols, which can be 
tailored to specific projects. The open-source software interface enables researchers to model 
their projects around the up-to-date tissue bank archives to ensure that they will have seamless 
access to the material they require to fulfill the stated research objectives in various grant-funded 
initiatives, in addition to allowing them to plan future endeavors around previously collected 










Advancements in cancer research, particularly in the specialties of molecular medicine and 
personalized therapeutic strategies, have significantly increased our understanding of cancer 
biology and have made great strides in the treatment of the disease. To further us down the path 
of personalized medicine and the promise of precision therapies that provide maximum 
effectiveness with minimal side-effects, the link between the clinical pathology laboratory and 
translational researchers must be strengthened to allow for a streamlined path of cutting-edge, 
clinically relevant investigations. The comprehensive three-fold biobanking strategy of the 
Edwards Comprehensive Cancer Center Tissue Procurement Department provides partnered 
researchers at rural institutions with a complete toolkit that they can use to further their research. 
The next-generation resources now available enable researchers to move seamlessly through the 
basic science discovery phase to functional assays on living cells to test their hypothesis. The 
complete disease models available to rural researchers at Marshall University and other 
researchers throughout the country have the potential to provide vital information about cancer 
biology and etiology, specifically in niche populations of rural southwestern Appalachia where 




The Edwards Comprehensive Cancer Center biorepository is a non-profit endeavor with a clear 
and concise mission statement: to advance cancer research in our region for the benefit of our 
community. Donors to the tissue bank are aware that they will receive no direct benefit from 
their contribution. However, advancements derived from their donations may contribute to a high 
standard of care in the future treatment of cancer. The advancements in cancer biobanking at the 
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, with its direct 
partnership with the pathology practice of Marshall University's Joan C. Edwards School of 
Medicine, is opening new doors and providing new opportunities to rural research institutions. 
The program is continuing to advance in size and scope, with future collection sites and 
partnerships with other biorepositories in the state of West Virginia currently being investigated. 
Supplementary research services in clinical histopathology and research consultations are also 
being expanded to further the work of basic scientists in their investigations. With the growing 
capabilities of the tissue procurement department and the expansion of the diagnostic pathology 
department, we hope in the future to grow our research capacities to include other specialty 
areas, such as molecular pathological studies and genetic analysis. We hope that the Tissue 
Procurement Program will continue to be an ever-expanding bank of valuable source material for 
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